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Glucocorticoid (GC) therapies may adversely cause insulin resistance (IR) that lead to a compensatory hyperinsulinemia due to
insulin hypersecretion. The increased 𝛽-cell function is associated with increased insulin signaling that has the protein kinase
B (AKT) substrate with 160 kDa (AS160) as an important downstream AKT effector. In muscle, both insulin and AMP-activated
protein kinase (AMPK) signaling phosphorylate and inactivateAS160,which favors the glucose transporter (GLUT)-4 translocation
to plasma membrane. Whether AS160 phosphorylation is modulated in islets from GC-treated subjects is unknown. For this, two
animal models, Swiss mice andWistar rats, were treated with dexamethasone (DEX) (1mg/kg body weight) for 5 consecutive days.
DEX treatment induced IR, hyperinsulinemia, and dyslipidemia in both species, but glucose intolerance and hyperglycemia only in
rats. DEX treatment caused increased insulin secretion in response to glucose and augmented 𝛽-cell mass in both species that were
associated with increased islet content and increased phosphorylation of the AS160 protein. Protein AKT phosphorylation, but not
AMPK phosphorylation, was found significantly enhanced in islets from DEX-treated animals. We conclude that the augmented
𝛽-cell function developed in response to the GC-induced IR involves inhibition of the islet AS160 protein activity.
1. Introduction
Glucocorticoids (GCs), such as dexamethasone (DEX), are
widely prescribed in clinical practice due to their anti-
inflammatory, antiallergic, and immunosuppressive proper-
ties. GCs are the standard treatment for asthma, rheumatoid
arthritis, systemic lupus erythematosus, and inflammatory
bowel diseases [1, 2], as well as the protection against rejection
of transplanted organ [1]. However, supraphysiological levels
of GCs (either exogenous or endogenous) induce adverse
effects related to glucose homeostasis, such as decreased
peripheral insulin sensitivity, glucose intolerance, and dys-
lipidemia [3–6]. Depending on the genetic background, age,
and time and dose of the exposure, it can also lead to type 2
diabetes mellitus (T2DM) [4, 6–11].
T2DM is a multifactorial metabolic disease mainly char-
acterized by hyperglycemia [12], but before the occurrence
of overt hyperglycemia, peripheral insulin resistance (IR)
leads to compensatory insulin hypersecretion by pancreatic
islets [13]. This adaptive islet compensation leads to a state of
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hyperinsulinemia together with normoglycemia or a modest
increase in glycemic values (prediabetic state) that persist
until the 𝛽-cells can handle the required demand for insulin
[14].Themajormechanisms by which 𝛽-cells generate hyper-
insulinemia during adaptive compensation consist of func-
tional (e.g., increased insulin biosynthesis and/or secretion)
and structural adaptations (e.g., increased 𝛽-cell hyperplasia
and hypertrophy that may result in increased 𝛽-cell mass)
[14–16]. Thus, when 𝛽-cells can no longer compensate, a glu-
colipotoxicity process progressively develops that induces 𝛽-
cell death accompanied by hypoinsulinemia, hyperglycemia,
and hyperlipidemia [15].
The 𝛽-cell compensations [17] can be rapidly obtained
experimentally by 5-day treatment with DEX (5 days) [18, 19]
that induces peripheral IR [20, 21], which is associated with
increased hepatic gluconeogenesis and lipolysis [8].
Rats and mice are widely used as laboratory models to
elucidate the mechanisms (at the functional, structural, and
molecular levels) involved in the pancreatic islets compen-
sations during the development of T2DM, such as observed
in GC-induced IR [9, 10, 18–27]. These compensations are
strongly associated with increased insulin signaling in islets
(insulin receptor [Ir] and the protein kinase B [AKT]) [9,
19, 25, 28]. The AKT1 overexpression in 𝛽-cells lead to
increased isletmass [29], while the𝛽-cell-specific Ir knockout
(𝛽IrKO) lead to reduced glucose-stimulated insulin secretion
(GSIS), lower islet insulin content, and glucose intolerance,
supporting the consensus that the loss of insulin action on
𝛽-cells leads to 𝛽-cell failure and T2DM [30].
It has been demonstrated that a major downstream
effector of AKT, the AKT substrate with 160 kDa (AS160),
previously recognized as an important protein in insulin
signaling in skeletal muscles and adipose tissue, is found to
be expressed in 𝛽-cells and is also a major effector of AKT in
the 𝛽-cell [31, 32].
In skeletal muscles, both insulin and AMP-activated
protein kinase (AMPK) pathways phosphorylate and inhibit
AS160 [32], inducing the trafficking of vesicles containing
glucose transporter-4 (GLUT4) to the plasma membrane
[33, 34]. In 𝛽-cells, AS160 plays an important role in the
GSIS [31] and evidences suggest that AS160 is also involved
in the trafficking of vesicles containing insulin to the plasma
membrane [35]. AS160 is expressed in human islets and its
phosphorylation is increased when stimulated with glucose
(16.7mmol/L) [31]. Also, T2DM humans display reduced
AS160 mRNA and the AS160 knockdown in primary mouse
islets lead to increased basal insulin secretion (2.8mmol/L
glucose), whereas GSIS (16.7mmol/L glucose) is impaired
[31].
Considering the importance that has been given to the
involvement of the AS160 in islet function, we sought to
investigate whether the AS160 content and phosphorylation
could bemodulated by theGC treatment. By using two exper-
imentalmodels, Swissmice andWistar rats, we demonstrated
that the augmented 𝛽-cell function (insulin hypersecretion
and increased 𝛽-cell proliferation) caused by 5-day DEX
administration is associated with significant reduction of the
AS160 protein content and marked increase of the AS160
protein phosphorylation in islets of both insulin-resistant
rodents. Furthermore, this AS160 inhibition is islets from
GC-treated animals which were accompanied by high AKT,
but not AMPK phosphorylation.
2. Materials and Methods
2.1. Reagents. Dexamethasone phosphate (Decadron) was
purchased from Ache´ (Campinas, SP, Brazil). Human
recombinant insulin (Humalin R) was obtained from
Lilly (Indianapolis, IN, USA). Trizol was purchased from
Gibco-BRL (Gaithersburg, MD, USA) and Triton X-100 was
purchased from Cromato Products (Diadema, SP, BR). The
125I-labeled insulin used in the radioimmunoassay (RIA)
was purchased from Perkin Elmer (Boston, MA, USA).
SDS-PAGE and immunoblotting were performed using
Bio-Rad systems (Hercules, CA, USA), and all chemicals
were from Bio-Rad and Sigma Aldrich (St. Louis, MO, USA).
Western blot detection of specific proteins used the following
primary antibodies from Santa Cruz (Santa Cruz, CA,
USA): anti-phospho-Ir-𝛽Tyr1162/1163, anti-Ir-𝛽, anti-phospho-
AKT
1/2/3
Thr308, anti-AKT
1/2/3
, anti-phospho-ERKTyr204,
anti-ERK
1
, anti-PKC, and anti-GAPDH. Anti-phospho-
AMPKThr172, anti-AMPK, anti-phospho-ACCSer79, anti-ACC,
anti-phospho-AS160Thr642, anti-phospho-PKC substrates,
and anti-PCNA were from cell signaling (Temecula, CA,
USA). Anti-phospho-mTORSer2448 and anti-mTOR were
from Abcam (Cambridge, UK), and anti-CX36 was from
Invitrogen (Camarillo, CA, USA). The secondary antibodies
used were anti-rabbit IgG and anti-mouse IgG from cell
signaling. Urea antiprotease/antiphosphatase buffer was
composed of 7M urea, 2M thiourea, 5mmol/L EDTA,
1mmol/L sodium fluoride, 1mmol/L sodium orthovanadate,
1mmol/L sodium pyrophosphate, 2mM PMSF, 1% Triton
X-100, and 1 𝜇g/mL aprotinin (Trasylol from Bayer Health
Care Pharmaceuticals, Berkley, CA). Immunohistochemical
detection of insulin was performed using an anti-insulin
primary antibody (guinea pig polyclonal) (Dako, Carpinteria,
CA, USA) and detection of KI-67 was performed using an
anti-KI-67 antibody (Spring Bioscience, Pleasanton,
CA, USA). The secondary antibodies used to detect the
anti-insulin and anti-KI-67 antibodies were anti-guinea
pig IgG (Invitrogen, Carlsbad, CA, USA) and HRP-
conjugated anti-rabbit IgG (Nichirei Bioscience, Tokyo, JP),
respectively.
2.2. Animals and Experimental Design. Experiments were
performed on groups of male Swiss mice and male Wistar
rats (80 to 100 days) obtained from the State University of
Campinas Animal Breeding Center. They were maintained
in appropriate animal cages and kept at 24∘C on a 12 : 12-
hour light-dark cycle. Both mice and rats had access to
food and water ad libitum. The experiments with ani-
mals were approved by the Institutional State University of
Campinas Committee for Ethics in Animal Experimentation
under protocol number 2285-1. Mice and rats were divided
into the following two groups: DEX-treated rodents (DEX)
that received a daily injection of dexamethasone phosphate
(intraperitoneally (i.p.), 1.0mg/kg body weight (b.w.) in 0.9%
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NaCl for 5 consecutive days) and control rodents (CTL) that
received a daily injection of saline (i.p., 1.0mL/kg b.w., for 5
consecutive days) between 08:00 and 09:00. All experiments
were performed 24 h after the last DEX injection (at the sixth
day) to avoid the overlapping of acute and chronic effects of
GCs.
2.3. Metabolic, Hormonal, and Biochemical Measurements.
Body weight was measured 2 days before the start of treat-
ment and each day thereafter until the day of euthanasia.
On the day after the last DEX administration, blood was
collected from the tails of a group of fasted (10–12 h) animals
and blood glucose levels were measured with a glucome-
ter (Accu-Chek Advantage, Roche Diagnostic, Switzerland).
Immediately after blood glucose determination, the animals
were sacrificed (by exposure toCO
2
followed by decapitation)
and the trunk blood was collected. The serum was obtained
by centrifugation and was used to measure the following
parameters: insulin by RIA, nonesterified-free-fatty-acids
(NEFA) (Wako Chemicals; Richmont, USA), triacylglycerol
(TG), and total cholesterol (CHOL) (Roche/Hitachi; Indi-
anapolis, IN, USA) by spectrophotometer according to the
manufacturers’ instructions.
2.4. Intraperitoneal Insulin Tolerance Test (ipITT). A separate
group of fed animals received an intraperitoneal injection
of insulin (1 U/kg b.w. in 0.9% NaCl). Blood glucose was
measured at baseline (before insulin administration; 0min)
and at 5, 10, 15, 30, 45, and 60min after insulin adminis-
tration. Blood glucose measurements were then converted
into the natural logarithm (Ln); the slope was calculated
using linear regression (time × Ln[glucose]) and multiplied
by 100 to obtain the constant rate of glucose decay per minute
(%/minute) during the ipITT (KITT) [12].
2.5. Intraperitoneal Pyruvate Tolerance Test (ipPTT). A sepa-
rate group of fasted (14 h) animals received an i.p. injection
of pyruvate (1 g/kg b.w.). Blood glucose was measured at
baseline (before pyruvate administration; 0min) and at 5,
15, 30, and 60min after pyruvate administration. The area-
under-curve (A.U.C.) for blood glucose values was obtained
from the 30min of the ipPTT after normalization of the data
[10]. The constant rate of glucose appearance per minute
(%/min) during the first 15min of the ipPTT (KPTT) was
calculated as described above.
2.6. Intraperitoneal Glucose Tolerance Test (ipGTT). A sepa-
rate group of fasted (10 h) animals received an i.p. injection
of 25% glucose solution (1 g/kg b.w.). Blood glucose was
measured at baseline (before glucose administration; 0min)
and at 15, 30, 60, 90, and 120min after glucose administration.
The A.U.C. was calculated as described above.
2.7. Islet Isolation and Static Insulin Secretion. Islets were
isolated by collagenase digestion of the pancreas as described
[27]. Insulin secretion and quantification by RIA were per-
formed using a similar method as described previously [10].
2.8. Immunohistochemistry and Morphometry in the Endo-
crine Pancreas. For morphometric analysis, at least 6 pan-
creases from each group of mice and rats were removed,
weighed, and fixed for 24 hours in 4% paraformaldehyde
solution, as previously described [25]. For morphometry
analysis, all islets present in the sections were obtained
systematically by capturing images with a digital cam-
era (Olympus DP52, Tokyo, JP) coupled to a microscope
(Olympus BX51TF, Tokyo, JP). The islet, 𝛽-cell and sec-
tion areas were analyzed using the free software ImageJ
(http://rsbweb.nih.gov/ij/download.html). The relative 𝛽-cell
area was calculated by dividing the 𝛽-cell area per section
by the total pancreas area per section and the absolute 𝛽-
cell mass was calculated by multiplying the pancreas weight
by the relative 𝛽-cell area per pancreas. The relative number
of islets was obtained by dividing the number of islets per
section by the total area of the section [25].
2.9. 𝛽-Cell Proliferation. Average 𝛽-cell proliferation was
obtained by counting the total islet cell nuclei stained for
insulin and KI-67 using the same software cited above. 𝛽-cell
proliferation was estimated by dividing the number of KI-67-
positive nuclei by the total number of insulin-positive cells
[25].
2.10. 𝛽-Cell Death. Fragmented DNA was isolated using
buffer 𝐴 containing 50 nM Tris-Hcl pH 8.1, 10 nM EDTA,
and 1% Triton X100. Total DNA was isolated using buffer
𝐵 containing 50 nM Tris-Hcl pH 8.1, 10 nM EDTA, and 1%
SDS. After isolation, total DNA and fragmented DNA were
precipitated with phenol, chloroform and isoamyl alcohol
(25 : 24 : 1) and quantified by SybrGreen fluorescence using
a standard curve (0.5 ng/mL to 50 ng/mL). The data are
expressed as the ratio of fragmented to total DNA.
2.11. Protein Extraction and Immunoblotting. Protein extrac-
tion and immunoblotting were performed as previously
reported [36] with minor modifications. Images were cap-
tured by the luminescent image analyzer LAS-3000 (Fujifilm,
Tokyo, JP) and the specific band intensity was quantified by
optical densitometry using ImageJ.
2.12. RNA Isolation and Quantitative RT-PCR Analysis.
Groups of 600 islets were homogenized in Trizol following
phenol chloroform RNA extraction, as previously described
[36]. Relative quantities of target transcripts were calculated
from duplicate samples after normalization of the data
against the endogenous control, GAPDH. The primers used
were as follows: PDX1 (S: aaccggaggagaataagagg and AS:
gttgtcccgctactactgtt), insulin (S: ttgcagtagttctccagtt and AS:
attgttccaacatggccctgt), and GAPDH (S: cctgcaccaccaactgctta
and AS: gccccacggccatcacgcca).
2.13. Statistical Analysis. The results are expressed as the
mean ± s.e.m. of the indicated number (𝑛) of animals. A
paired or unpaired Student’s 𝑡-test was used for intragroup
(before and after) or intergroup (CTL versus DEX group)
comparisons. All analyses were performed using GraphPad
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Table 1: Body and adrenal weight in DEX-treated mice and rats.
Mice Rats
Body weight (g) Adrenal weight (mg/100 g b.w.) Body weight (g) Adrenal weight (mg/100 g b.w.)
Before After After Before After After
CTL 38.7 ± 0.6 40.2 ± 0.6 18.21 ± 1.74 340.1 ± 6.5 351.2 ± 11.5 17.5 ± 1.12
DEX 39.4 ± 0.8 37.9 ± 0.7† 12.68 ± 0.72∗ 346.7 ± 11.2 309.6 ± 10.8† 11.38 ± 0.78∗
†Significantly different using unpaired 𝑡-test versus DEX before treatment; ∗significantly different using unpaired 𝑡-test versus CTL after treatment 𝑃 < 0.05;
𝑛 = 6–8; values are mean ± s.e.m.
Table 2: Metabolic variables in 12 hour fasting DEX-treated mice and rats.
Mice Rats
CTL DEX CTL DEX
Cholesterol (mg/dL) 169.7 ± 14.2 302.0 ± 18.3∗ 23.8 ± 1.8 30.6 ± 1.7∗
Triacylglycerol (mg/dL) 106.9 ± 12.4 201.0 ± 13.8∗ 111.2 ± 14.2 210.1 ± 26.6∗
NEFA (mMol/L) 1.2 ± 0.09 1.1 ± 0.08 0.6 ± 0.04 0.9 ± 0.09∗
Glycemia (mMol/L) 5.5 ± 0.3 5.0 ± 0.4 5.5 ± 0.08 8.8 ± 0.8∗
Insulinemia (pMol/L) 31.9 ± 3.09 59.9 ± 9.6∗ 268.6 ± 64.3 2697.4 ± 439.0∗
∗Significantly different using unpaired 𝑡-test versus CTL 𝑃 < 0.05; 𝑛 = 8–10; values are mean ± s.e.m.
Prism version 5.0 (GraphPad Software, SanDiego, CA, USA).
A𝑃 value less than or equal to 0.05was considered significant.
3. Results
3.1. DEX Treatment Reduced Body and Adrenal GlandWeights
in Mice and Rats. It is known that 5-day DEX treatment in
rats produces a dose-dependent reduction in adrenal gland
mass in a reciprocal reduction of endogenous corticosterone
concentration [10]. As expected, DEX treatment induced a
significant decrease in the mass of the adrenal glands in mice
(30%) and rats (35%) compared with their respective controls
(Table 1), which demonstrates the effectiveness of exogenous
GC treatment on adrenal hypotrophy. In addition, the mice
and rats showed reduced body weight (4% and 11%, resp.)
(Table 1), which is a feature commonly observed in rats made
insulin-resistant by DEX treatment [10, 37].
3.2. DEX Treatment Induced a Reduction in Insulin Sensitivity
in Mice and in Rats but Increased Hepatic Gluconeogenesis
and Glucose Intolerance Only in Rats. We first confirmed the
reduction in insulin sensitivity in both mice and rats. The
ipITT revealed a significant reduction in insulin sensitivity
in both DEX-treated groups (Figures 1(a) and 1(f), resp.) as
indicated by the reduction in the KITT (inset in Figures
1(a) and 1(f)), although this effect occurred to a lesser
extent in mice. We also analyzed whether GC treatment
increased hepatic gluconeogenesis. DEX treatment did not
alter gluconeogenesis in mice; however, DEX-treated rats
showed increased glucose production in response to pyruvate
administration, as indicated by the increased A.U.C. and
the KPTT (Figures 1(b)–1(d) and 1(g)–1(i), resp.), which
indicates hepatic insulin resistance. Despite a reduction in
insulin sensitivity, DEX-treated mice remain glucose tolerant
(Figure 1(e)). Compared to their controls, DEX-treated rats
showed the well-known negative impact of GC excess on
glucose tolerance (Figure 1(j)), which reflects the association
of increased hepatic glucose production with a possible
reduction of peripheral glucose disposal.
3.3. DEX Treatment Induced Dyslipidemia and Hyperinsu-
linemia in Both Mice and Rats. DEX treatment increased
fasting serum cholesterol (CHOL) and triacylglycerol (TG)
concentrations in both mice and rats compared to their
respective controls, which indicates a negative impact of
GCs on lipid metabolism in both species. In addition, DEX
treatment increased the NEFA levels only in rats (Table 2),
which may indicate an increased rate of lipolysis of adipose
tissue. DEX-treated rodents also showed a marked increase
in serum insulin levels that were 1- and 9-fold higher in mice
and rats, respectively. Blood glucose was not altered in DEX-
treated mice, while it was 60% higher in DEX rats compared
to CTL (Table 2). Thus, the hyperinsulinemia corroborates
the IR state and seems to protect against the disruption of
glucose homeostasis, though GC-treated rats were glucose
intolerant.
3.4. DEX Treatment Increased the Responsiveness to Glucose
in Islets from Both Mice and Rats. Due to the increased
insulinemia that was observed in both DEX-treatedmice and
rats, we assessed the GSIS. Compared to the control groups,
isolated islets from DEX-treated rats were more responsive
to all glucose concentrations used (from 2.8mmol/L to
22.2mmol/L), (Figures 2(c) and 2(d)), whereas islets from
DEX-treated mice were more responsive to glucose up to
a concentration of 11.1mmol/L (Figures 2(a) and 2(b)).
These data point to species differences in the increase of
𝛽-cell function that contributes to the different degrees of
hyperinsulinemia found in each species.
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Figure 1: DEX treatment induces a reduction in insulin sensitivity in mice and in rats but increases hepatic gluconeogenesis and glucose
intolerance only in rats. ((a), (f)) Blood glucose during intraperitoneal insulin tolerance test (ipITT; 1 U/Kg b.w.) in DEX-treated mice and
rats, respectively; the inset in (a) and (f) depicts the constant rate of glucose disappearance (KITT). ((b), (g)) Intraperitoneal pyruvate tolerance
test (ipPTT; 1 g/Kg b.w.) in DEX-treated mice and rats, respectively; the inset in (b) and (g) depicts the ipPTT data normalized by minute 0
((c), (h)) A.U.C and ((d), (i)) the constant rate of glucose appearance (KPTT) during ipPTT in DEX-treated mice and rats, respectively. ((e),
(j)) intraperitoneal glucose tolerance test (ipGTT; 1 g/Kg b.w.) in DEX-treated mice and rats, respectively; the inset in (e) and (j) depicts the
A.U.C. from ipGTT; values are mean ± S.E.M.; 𝑛 = 8–10 animals per group. ∗Significantly different compared to CTL. Unpaired Student’s
𝑡-test, 𝑃 ≤ 0.05.
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Figure 2: Islets from DEX-treated rats are more responsive to glucose than islets from DEX-treated mice. ((a), (c)) Static cumulative insulin
secretion in isolated islets fromDEX-treated mice and rats in response to different glucose concentrations, respectively. ((b), (d)) Normalized
glucose-stimulated insulin secretion (GSIS) (fold increase in relation to 2.8mmol/L glucose) inmice and in rats, respectively. Values aremean
± S.E.M.; 𝑛 = 4–6 wells from 5 different animals. ∗Significantly different compared to CTL. Unpaired Student’s 𝑡-test, 𝑃 ≤ 0.05.
3.5. DEX Treatment Leads to Increased 𝛽-Cell Mass in the
Pancreas of Mice and Rats. Because an increase in 𝛽-cell
mass may also favor compensatory hyperinsulinemia, we
investigated this parameter in DEX-treated mice and rats.
Pancreatic sections stained for insulin revealed a significant
increase in the number of islets per pancreatic area in both
DEX-treated rats and mice compared to their respective
controls (Figures 3(a) and 3(c)). Additionally, DEX treat-
ment significantly increased the absolute 𝛽-cell mass in
the pancreas from both mice and rats (Figure 3(e)). These
data indicate a compensatory structural islet adaptation in
response to DEX-induced IR in both species.
3.6. DEX Treatment Increases 𝛽-Cell Proliferation without
Affecting Apoptosis in Mouse and in Rat Islet Cells. The 𝛽-cell
mass is the result of a dynamic balance between cell death
and proliferation.We found that DEX treatment significantly
increased 𝛽-cell proliferation in islets from rats (420%) and
mice (200%) compared with their respective controls, as
indicated by the higher number of KI-67-positive 𝛽-cell
nuclei (Figures 4(a) and 4(b)). In addition, DEX treatment
increased the protein content of the proliferating cell nuclear
antigen (PCNA) in islets to a greater extent in rats than in
mice (Figure 4(c)). DEX treatment did not affect apoptosis
in the islets of rats or mice as judged by DNA fragmentation
(Figure 4(d)) and caspase-3 cleavage data (Figure 4(e)).
3.7. Increased 𝛽-Cell Function and Mass Is Associated with
Increased Ir-𝛽/AKT and Reduced AMPK/ACC Pathway Activ-
ities in Pancreatic Islets from DEX-Treated Mice and Rats.
Because insulin plays an important role in insulin secretion
and in 𝛽-cell proliferation and can act directly upon the
islet cells, we investigated whether insulin signaling was
modulated by DEX treatment. We analyzed the canonical
insulin pathway through the insulin receptor𝛽-subunit (Ir-𝛽)
and its downstream protein, AKT. In islets fromDEX-treated
mice, we observed an increase in p-Ir-𝛽 (Figure 5(a)) without
alterations in the total Ir-𝛽 protein content (Figure 5(b)). In
islets from DEX-treated rats, the levels of p-Ir-𝛽 and total
Ir-𝛽 protein increased significantly (Figures 5(a) and 5(b)).
DEX-treated mice had increased islet p-AKT (Figure 5(c))
without alteration of the total AKT content (Figure 5(d)).
In rat islets, DEX treatment resulted in higher amounts
of p-AKT and total AKT (Figures 5(c) and 5(d)). We also
assessed whether the extracellular signal-regulated kinase
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Figure 3: DEX treatment increases 𝛽-cell mass in the pancreas of mice and rats. (a) Representative pancreas sections stained for insulin with
Hematoxylin counterstaining. (b) Pancreas weight, (c) relative islet number per pancreas area, (d) relative 𝛽-cell area per pancreas area, and
(e) absolute 𝛽-cell mass in DEX-treated mice and rats. Values are mean ± S.E.M.; 𝑛 = 5-6 animals per group (≈150 islets frommice and ≈300
islets from rats). ∗Significantly different compared to CTL. Unpaired Student’s 𝑡-test, 𝑃 ≤ 0.05.
(ERK) pathway, which can be activated by insulin and
participates in cell proliferation and differentiation [38], is
modulated by DEX treatment. In mice islets, only p-ERK
was augmented (Figures 5(e) and 5(f)), while DEX-treated
rat islets showed a significant increase in p-ERK and total
ERK content (Figures 5(e) and 5(f)).The AMPK pathway can
also modulate the insulin secretion [39]. Islets from DEX-
treated mice and rats had lower p-AMPK without alterations
in the total AMPK content (Figures 5(g) and 5(h)). ACC,
a downstream AMPK target protein, has diminished activity
when phosphorylated. In both species, DEX treatment was
associated with decreased levels of phosphorylated ACC
(Figure 5(i)) without altering the total ACC levels in islets
(Figure 5(j)), which indicates increased lipid synthesis in
islets. Thus, DEX treatment results in increased insulin and
decreased AMPK signaling pathways in islets from mice and
rats.
3.8. DEXTreatmentModulates Proteins Related toVesicle Traf-
ficking, Protein Synthesis, Cell Growth, and Insulin Secretion in
Pancreatic Islets from Both Mice and Rats. AKT and AMPK
pathways were modulated in islets from GC-treated rodents.
Since, in skeletal muscle, these pathways interact and inhibit
AS160 through phosphorylation, allowing the GLUT4 vesicle
trafficking to the plasma membrane [34], we investigated
whether AS160 could be modulated in islets from GC-
treated rodents. In mice and rats, DEX treatment resulted in
higher p-AS160 (Figure 6(a)) and lower total AS160 contents
(Figure 6(b)) compared to the control groups, which is in
accordance with increased GSIS and hyperinsulinemia. AKT
andAMPKpathway can alsomodulate themammalian target
of rapamycin (mTOR), a key protein that induces protein
synthesis. Islets from DEX-treated mice and rats showed
increased p-mTOR and totalmTORprotein (Figures 6(c) and
6(d)).
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Figure 4: DEX treatment increases 𝛽-cell proliferation without affecting apoptosis in the islets of mice and rats. (a) Representative pancreas
sections stained for insulin (on the top) and KI-67 (at bottom), (b) percentage of KI-67-positive nuclei (+) 𝛽-cell, (c) PCNA content, (d) DNA
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Due to its importance in the insulin secretion process, we
also investigated proteins related to calcium (Ca2+) influx,
such as protein kinase C (PKC) and connexin 36 (CX36).The
levels of phosphorylated PKC-target proteins (Figure 6(e)),
total PKC (Figure 6(f)), and CX36 (Figure 6(g)) were
increased in islets fromDEX-treated mice and rats compared
to their control groups. These data support an increased
insulin secretion and 𝛽-cell mass in DEX-treated rodents.
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3.9. DEX Treatment Is Associated with Increased mRNA Levels
of PDX1 in Rat Islets, but Not inMice Islets. We also evaluated
whether DEX treatment could alter the mRNA levels of the
insulin and pancreatic duodenal homeobox-1 (PDX1) genes.
DEX treatment tended to increase insulin mRNA levels in
pancreatic islets from both mice and rats (Figure 6(h); 𝑃 =
0.056 and 0.055, resp.). In addition, DEX treatment increased
PDX1 mRNA levels in rat islets, but not in mouse islets
(Figure 6(h)).
4. Discussion
In this study, we showed that in vivo GC treatment induced
IR, hyperinsulinemia, and dyslipidemia in both species, but
glucose intolerance and hyperglycemia only in rats. Both
species displayed increased 𝛽-cell function (insulin hyper-
secretion) and mass (𝛽-cell hyperplasia) as compensatory
mechanisms. These compensatory responses were associated
with reduced AS160 protein content and increased AS160
phosphorylation in islets as well as augmented AKT, but not
AMPK phosphorylation (Figure 7).
The alterations in insulin action as well as in plasma
insulin concentrations induced by theGC excess are compen-
sated by enhanced insulin secretion in response to glucose,
as can be frequently observed in GC-treated subjects [40–
43]. Despite the pronounced hyperinsulinemia that results
from a marked enhancement of the GSIS and increased 𝛽-
cell mass, DEX-treated rats were not able to properly coun-
teract the peripheral IR and both glucose intolerance and
hyperglycemia developed being in accordance with previous
studies [9, 19, 22, 37].
Although DEX-treated mice presented an increase in
peripheral IR, they remainednormoglycemic and glucose tol-
erant, indicating that the islet compensations (e.g., increased
GSIS and 𝛽-cell mass) were sufficient to prevent any sig-
nificant disruption of glucose homeostasis. Thus, at similar
conditions of treatment (time and doses of DEX), mice seem
to be less vulnerable than rats to the deleterious effects
of GCs upon glucose homeostasis. This difference between
species may be ascribed to difference in the GC receptor
expression or activity in GC responsive tissues and/or in the
GC metabolism, which does not exclude that for a more
prolonged period and/or higher GC concentrations mice
could develop an imbalance of the glucose homeostasis.
These species-specific responses to theGCs regarding glucose
tolerance highlight the importance to perform individualized
analysis in patients receiving GC-based therapies.
Basal hyperinsulinemia may be explained by several
factors, including the reduction of hepatic insulin clearance
[44] and/or an increase of basal insulin secretion [10, 18].
The data obtained regarding insulin secretion demonstrated
that both DEX-treated rats and mice had higher insulin
responses to glucose, including at subthreshold glucose levels
(e.g., 2.8mmol/L and 5.6mmol/L). It is well known that
hydrocortisone administration acutely suppresses insulin
release in mice by a mechanism that most likely involves
the central activation of sympathetic nerves [45]. This was
not the case here, as our experiments were performed 24 h
AMPK AKT
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mTOR
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Insulin secretion
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CX36
PKC
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GC[ ]
Ca2+
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↑
AMP
ATP
Figure 7: Hypothetical scheme of the main signaling pathways
modulated in pancreatic 𝛽-cells by the in vivo glucocorticoid
treatment. Decreased insulin sensitivity in peripheral tissues leads
to hyperinsulinemia, which stimulates the insulin signaling in the
pancreatic 𝛽-cell. Activated AKT inactivates the AS160, releasing
its inhibitory effect on insulin secretion (functional compensation).
Also, pAKT activates mTOR, favoring 𝛽-cell growth (structural
compensation). In parallel, dephosphorylated AMPK, which may
reflect a lowAMP :ATP ratio, favors the activation ofmTORbyAKT
and suggest that AS160 inhibition is modulated by the insulin sig-
naling, rather than AMPK signaling. An increased parasympathetic
drive through muscarinic receptor (M3) and/or increased 𝛽-cells
communication, through CX36 channels, may increase cytosolic
Ca2+ and activates PKC, which stimulates insulin secretion. →
represents stimulations and ⊣ represents inhibition.
after a 5-day course of DEX, thus eliminating the possible
overlapping of acute and chronic effects.
Basal hyperinsulinemia in DEX-treated rodents can also
be explained by the increased 𝛽-cell mass which is usually
observed in insulin-resistant rodents fed a high-fat [17] or
high sucrose diet [46]. Herein, we showed that increased
𝛽-cell mass resulted from, at least in part, increased 𝛽-cell
proliferation as judged by the increased PCNA and KI-67
expression.
𝛽-cell function that includes an increase of insulin
response to glucose and increased 𝛽-cell proliferation are
modulated by several stimuli through various intracellular
pathways, and one of these major stimuli is insulin itself. Pre-
vious studies have documented the important role of insulin
signaling in the 𝛽-cell function, survival, and growth [29,
30]. In our study, the compensatory insulin hypersecretion
and 𝛽-cell proliferation in both DEX-treated rodents were
associated with increased p-Ir-𝛽 and p-AKT in the islets,
corroborating the hypothesis that enhanced insulin pathway
(Ir-𝛽/AKT) signaling is a common mechanism involved in
the endocrine pancreas compensation, for example, after
exposition to GCs (Figure 7). A previous study elegantly
demonstrated that AKT overexpression sustains an elevation
of the 𝛽-cell function that includes an enhancement of both
GSIS and 𝛽-cell mass [29]. Our data with islet AKT protein
content and phosphorylation are in accordance with other
GC-related studies [19, 28]. Increased p-ERK also reinforces
the hypothesis that insulin is involved with the pancreatic
islet compensations during GC exposures. In DEX-treated
rats, the increased Ir-𝛽, AKT, and ERK total contents indicate
an additive pancreatic compensatory mechanism compared
to mice, in which the mechanism is limited to increased
phosphorylation of the aforementioned proteins.
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We also investigated the potential of AMPK signaling for
mediation of islet adaptation in this context of GC excess. In
muscle, AMPK is an energy-sensitizing enzyme that is active
at low cellular energy (increased AMP/ATP ratio) [47]. In
the 𝛽-cell lineage (MIN6), AMPK inhibition by glucose is
essential for the activation of the insulin secretion process
[39]. The decreased AMPK phosphorylation in islets from
both groups of DEX-treated rodents supports the increased
GSIS and may reflect the abundance of energy substrates
available in the plasma.AMPKdownregulation also underlies
the increase in ACC activity and also suggests higher energy
availability. Thus, we hypothesized that reduction in the
AMPK/ACC pathway is one of the important mechanisms
involved in the modulation of the altered insulin secretory
process found under GC treatment.
In muscle and adipose cells, the AS160 is recognized
as an inhibitor of GLUT4 vesicle trafficking to the plasma
membrane [34]. In muscle cells, both insulin and AMPK
signaling inhibit AS160 through phosphorylation, favoring
GLUT4 vesicle trafficking [34]. 𝛽-cells also express AS160
that seems to exert several actions on the GSIS, survival
and growth; and is under the control of insulin signaling
[31, 35]. The crosstalk between AMPK signaling with the
AS160 in islets is not yet well established.The increasedAS160
phosphorylation in islets from GC-treated rodents indicates
that insulin pathway, through the AKT, rather than the
AMPKpathway,mediates AS160 inhibition, thus favoring the
exocytosis of the insulin vesicles. In addition, the reduction
in the AS160 expression is another mechanism that may
contribute to increased insulin secretion (Figure 7).
The AKT and AMPK signaling also modulate mTOR
function, a kinase that integrates multiple cell signals [13, 48]
and regulates 𝛽-cell function and growth [48]. Our results
agree with those from previous studies [49, 50] and indicate
that the inhibition of AMPK and the activation of AKT
synergistically activate mTOR in islets from GC-treated mice
and rats, which may corroborate the increased GSIS and 𝛽-
cell mass.
Another mechanism that contributes to the increased
islet function after exposition to GCs may remain at the
improvement of Ca2+ handling in 𝛽-cells. A Ca2+ influx
contributes to the first (triggering) and second phase (ampli-
fying) of insulin secretion [51]. An additional increase in
intracellular Ca2+, under stimulatory glucose concentrations,
is associated with a higher GSIS in islets from GC-treated
rats [18]. The higher GSIS is also associated with increased
CX36 expression in islets [27], which synchronizes Ca2+
transit between 𝛽-cells across the islets [52]. Activation of
PKC, which is stimulated by Ca2+ and participates in the
amplification of insulin secretion, is another mechanism
associated with increased GSIS in rats treated with GCs [18].
Here, we also observed an increase inCX36 expression and an
indirect increase in PKC activity in islets from both rats and
mice treated with GCs, indicating the participation of Ca2+
in increased 𝛽-cell function. Finally, increased expression of
𝛽-cell markers (PDX1 mRNA) only in DEX-treated rats islets
indicates that pancreatic compensations in this species also
involve modifications at transcriptional levels.
5. Conclusions
We conclude that in vivo GC treatment induced in rodents,
rats and mice, the deleterious effect on glucose homeostasis
as observed in humans (IR, hyperinsulinemia, and dyslipi-
demia), which were compensated by the increased GSIS and
𝛽-cell mass. These compensations were associated with islet
upregulation of AKT, but not AMPK signals that parallel with
inhibited AS160 activation (Figure 7). We suggest that basal
hyperinsulinemia in GC treated subjects may also involve the
inhibition of AS160 in 𝛽-cells.
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